Clik here to view.
Vertical Pharma to distribute Cipher’s tramadol in U.S.
Cipher Pharmaceuticals (TSX:DND) has entered into a distribution and supply agreement with Vertical Pharmaceuticals to market Cipher’s CIP-TRAMADOL ER in the U.S. for the treatment of moderate to...
View ArticleClik here to view.
Cipher signs up Canadian distributor for Tramadol
Cipher Pharmaceuticals (TSX:DND) has entered into a distribution and supply agreement with Medical Futures, a closely held Canadian pharmaceutical company, for the marketing of Durela in Canada. Durela...
View ArticleClik here to view.
Cipher readies regulatory filings for acne product
Cipher Pharmaceuticals (TSX:DND) is on track to file Health Canada and FDA submissions this quarter for its high-potential acne product, CIP-Isotretinoin, which is expected to trigger a $1 million...
View ArticleClik here to view.
Alitair builds value without outside investors
Dr. William W. Howard likes to say there’s a lesson to be learned in how closely held Alitair Pharmaceuticals has spent the first couple years of its existence developing a portfolio of respiratory...
View ArticleClik here to view.
Health Canada accepts Cipher acne filing for review
Health Canada has accepted for review a New Drug Submission by Cipher Pharmaceuticals (TSX: DND) for its CIP-Isotretinoin, a novel, patented formulation of the acne medication isotretinoin. The company...
View ArticleClik here to view.
Cipher partner launches of Durela in Canada
Cipher Pharmaceuticals’ (TSX:DND; OTCBB:CPHMF) partner, Medical Futures, has launched Durela, an extended-release tramadol product, in key markets across Canada, with a dedicated sales force of about...
View ArticleClik here to view.
Cipher posts strong second quarter results
Cipher Pharmaceuticals (TSX:DND; OTCBB: CPHMF) has posted second quarter profit of $200,000, compared with a year earlier loss of $500,000, on a 124% jump in revenue to $1.6-million. “It was an...
View ArticleClik here to view.
Cipher partner launches Absorica in U.S.
Cipher Pharmaceuticals (TSX:DND; OTCBB:CPHMF) announced that its partner, Ranbaxy Laboratories, has begun the sales and promotion of Absorica, Cipher’s novel, patented, brand formulation of the acne...
View ArticleClik here to view.
Tecnofarma to distribute Cipher’s tramadol
Cipher Pharmaceuticals (OTCBB:CPHMF; TSX:DND) has entered into a definitive distribution and supply agreement with Tecnofarma International, giving Tecnofarma the exclusive right to market, sell and...
View ArticleClik here to view.
Cipher Pharma adopts 5-by-5 mantra for future growth
Cipher Pharmaceuticals (OTCBB:CPHMF; TSX:DND), with newly installed CEO, Shawn O’Brien, has adopted a five-by-five strategy that sets objectives for its future growth. Shawn O’Brien “I want to...
View ArticleClik here to view.
Cipher readying tramadol launch in first quarter 2011
Cipher Pharmaceuticals (TSX: DND) is “working diligently” to finalize a marketing partnership and is finalizing commercial manufacturing requirements for its extended-release tramadol drug, which was...
View ArticleClik here to view.
Cipher Pharma adopts 5-by-5 mantra for future growth
Cipher Pharmaceuticals (OTCBB:CPHMF; TSX:DND), with newly installed CEO, Shawn O’Brien, has adopted a five-by-five strategy that sets objectives for its future growth. Shawn O’Brien “I want to...
View Article